WELCOME TO OUR PRACTICE

Size: px
Start display at page:

Download "WELCOME TO OUR PRACTICE"

Transcription

1 979 E. Third ST, STE A-240 Chattanooga, TN Phone- (423) Fax- (423) WELCOME TO OUR PRACTICE I wanted to thank you for choosing ReNu Chattanooga. I pledge to you that my staff and I will do our best to provide you and your family with high quality, state-of-the-art care in a professional and comfortable environment. Enclosed with this letter are some forms I need you to complete and have with you when you come to your appointment. Having these completed and ready when you arrive will speed yours and other patient s wait time. We look forward to your visit. If you have any questions before then, please call the office at (423) Sincerely, Paula Nicola, MD

2 979 E. Third ST, STE A-240 Chattanooga, TN Phone- (423) Fax- (423) WELCOME TO OUR PRACTICE I wanted to thank you for choosing ReNu Chattanooga. I pledge to you that my staff and I will do our best to provide you and your family with high quality, state-of-the-art care in a professional and comfortable environment. Enclosed with this letter are some forms I need you to complete and have with you when you come to your appointment. Having these completed and ready when you arrive will speed yours and other patient s wait time. We look forward to your visit. If you have any questions before then, please call the office at (423) Sincerely, Paula Nicola, MD

3 PAULA NICOLA, M.D. ERLANGER MEDICAL MALL 979 EAST THIRD STREET. SUITE 240 CHATTANOOGA, TN PHONE FAX Registration Form PATIENT INFORMATION Patient Full Name: Marital Status: SSN: Street Address: Birthdate: Age: Sex: City: State: Zip: Home or Cell Phone: CONTACT PREFERENCES: Emergency Contact Name: Relationship: Phone: Restrictions The above person is authorized to receive information from ReNu Chattanooga regarding my care. This information may include but is not limited to test results, appointment information, and account information etc. Initial PRIVACY POLICY I acknowledge that I have read and fully understand the Notice of Privacy Practices given to me with this form. Initial FINANCIAL POLICY AGREEMENT ReNu Chattanooga does not accept or file to any insurance plans. These services will be provided on a self pay basis and all fees will need to be paid upfront prior to being seen. $375-First visit with induction (covers first 28 days of treatment only) (Medication is not included) $175- Each visit after the first 28 days of treatment We accept cash, checks, visa, mastercard and discover I understand and agree to pay all fees upfront prior to being seen. Intial The above information is true to the best of my knowledge. Patient Signature: Date:

4 PAULA NICOLA, M.D. ERLANGER MEDICAL MALL 979 EAST THIRD STREET. SUITE 240 CHATTANOOGA, TN PHONE FAX Patient Treatment Contract Patient Name: Date: As a participant in medication treatment for opioid misuse and dependence, I freely and voluntarily agree to accept this treatment contract as follows: 1. I agree to keep and be on time to all of my scheduled appointments. A $50.00 fee will be assessed to any patient who does not keep a scheduled appointment and does not call 2 hours prior to the appointment time to reschedule. This $50.00 fee must be paid prior to being seen again by the doctor or receiving any future prescriptions. Initial 2. I agree to adhere to the payment policy outlined by this office. ReNu Chattanooga and Dr. Nicola do not file any insurance for your office visits. All office visits must be paid in full prior to being seen by the doctor. Payment can be by Cash or Debit/Credit Card only. Initial 3. I agree to conduct myself in a courteous manner while at the doctor s office to other patients, to the office staff and to Dr. Nicola. Initial 4. I agree to be properly dressed for all appointments. Any patient who shows up for an appointment looking unkempt will be discharged from the practice. Initial 5. I agree to report my history and symptoms honestly to my doctor and the office staff. I will inform my doctor about any medications (prescription and non-prescription) that I am taking. I will report any changes in my medical history, such as becoming pregnant. Initial 6. I agree not to sell, share, or give any of my medication to another person. I understand that such mishandling of my medication is illegal and is a serious violation of this agreement and would result in my treatment being terminated without any recourse for appeal. Initial 7. I understand that my medication must be stored safely, where it cannot be taken accidentally by children or pets, or stolen. If anyone else, including a child, takes my medication, I will call 911 or Poison Control immediately. Initial 8. I agree not to deal drugs, steal, or conduct any illegal or disruptive activities in or around the doctor s office. Initial 9. I understand that if dealing or stealing or if any illegal or disruptive activities are observed or suspected by employees of the pharmacy where my medication is filled, that the behavior will be reported to my doctor s office and could result in my treatment being terminated without any recourse for appeal. Initial 10. I agree that my prescription can only be given to me at my regular office visits. A missed visit will result in my not being able to get my prescription until the next scheduled visit. Initial 11. I will be careful with my take-home prescription supplies of my medication as I understand that Suboxone film and all other buprenorphine-containing medications are potent and very dangerous for children. Even small amounts or a brief exposure to Suboxone film/buprenorphine products can lead to permanent damage and/or death in children. Initial 12. I understand that at every visit, my doctor may ask me to bring my unused supply of medication for a medication count and that I may not get a refill if I do not bring my medication with me. This includes empty film pouches which will be counted by the staff at each visit. Initial

5 13. I agree that the medication I receive is my responsibility and I agree to keep it in a safe, secure place. I agree that lost medication will not be replaced regardless of why it was lost. Initial 14. I agree not to obtain medications from any doctors, pharmacies, or other sources without telling my treating physician. Initial 15. I understand that mixing this medicine with other medications, especially benzodiazepines (for example, Valium, Ativan, Klonopin, or Xanax) can be dangerous. I also recognize that several deaths have occurred among persons mixing buprenorphine and benzodiazepines (especially if taken outside the care of a physician, using routes of administration other than sublingual or in higher than recommended therapeutic doses). Initial 16. I agree to read the Medication Guide and consult my doctor should I have any questions or experience any adverse events. Initial 17. I agree to take my medication as my doctor has instructed and not to alter the way I take my medication without first consulting my doctor. Initial 18. I understand that medication alone is not sufficient treatment for my condition, and I agree to participate in counseling as discussed and agreed upon with my doctor and specified in my treatment plan. Prescriptions may be withheld if I do not participate in some form of counseling at the discretion of the doctor. Initial 19. I agree to abstain from alcohol, opioids, marijuana, cocaine and other addictive substances (except nicotine). Initial 20. I agree to provide random urine samples as requested. Initial 21. I understand that violations of the above may be grounds for termination of treatment. Initial 22. I understand that ReNu Chattanooga shares office space with another practice. I agree to only come by the office on the date and time of my scheduled appointment to see Dr. Nicola. She will not be available at times outside of this to provide prescriptions for Suboxone film or any other medications. Initial 23. I understand that Dr. Nicola will only prescribe Suboxone film therapy except under very particular circumstances (i.e. pregnancy). No monotherapy product such as Subutex will be prescribed. Initial Patient Signature: Date:

6 NOTICE OF PRIVACY PRACTICES ReNu Chattanooga 979 E Third ST STE A240 Chattanooga, TN (423) Treatment-We use medical information about you to provide your medical care. We disclose medical information to our employees and others who are involved in providing the care you need. For example, we may share your medical information with other physicians or other health care providers who will provide services that we do not provide. Or we may share this information with a pharmacist who needs it to dispense a prescription to you, or a laboratory that performs a test. We may also disclose medical information to members of your family or others who can help you when you are sick or injured, or after you die. Payment- We use and disclose medical information about you to obtain payment for the services we provide. For example, we give your health plan the information it requires before it will pay us. We may also disclose information to other health care providers to assist them in obtaining payment for services they have provided to you. Health Care Operations-We may use and disclose medical information about you to operate this medical practice. For example, we may use and disclose this information to review and improve the quality of care we provide, or the competence and qualifications of our professional staff. Or we may use and disclose this information to get your health plan to authorize services or referrals. We may also use and disclose this information as necessary for medical reviews, legal services and audits, including fraud and abuse detection and compliance programs and business planning and management. We may also share your medical information with our "business associates," such as our billing service, that perform administrative services for us. We have a written contract with each of these business associates that contains terms requiring them and their subcontractors to protect the confidentiality and security of your protected health information. We may also share your information with other health care providers, health care clearinghouses or health plans that have a relationship with you, when they request this information to help them with their quality assessment and improvement activities, their patient-safety activities, their population-based efforts to improve health or reduce health care costs, their protocol development, case management or care-coordination activities, their review of competence, qualifications and performance of health care professionals, their training programs, their accreditation, certification or licensing activities, or their health care fraud and abuse detection and compliance efforts. Sale of Health Information- We will not sell your health information without your prior written authorization. The authorization will disclose that we will receive compensation for your health information if you authorize us to sell it, and we will stop any future sales of your information to the extent that you revoke that authorization. Required by Law- As required by law, we will use and disclose your health information, but we will limit our use or disclosure to the relevant requirements of the law. When the law requires us to report abuse, neglect or domestic violence, or respond to judicial or administrative proceedings, or to law enforcement officials, we will further comply with the requirement set forth below concerning those activities. Public Health- We may, and are sometimes required by law, to disclose your health information to public health authorities for purposes related to: preventing or controlling disease, injury or disability; reporting child, elder or dependent adult abuse or neglect; reporting domestic violence; reporting to the Food and Drug Administration problems with products and reactions to medications; and reporting disease or

7 Infection exposure- When we report suspected elder or dependent adult abuse or domestic violence, we will inform you or your personal representative promptly unless in our best professional judgment, we believe the notification would place you at risk of serious harm or would require informing a personal representative we believe is responsible for the abuse or harm. Health Oversight Activities- We may, and are sometimes required by law, to disclose your health information to health oversight agencies during the course of audits, investigations, inspections, licensure and other proceedings, subject to the limitations imposed by law. Judicial and Administrative Proceedings-We may, and are sometimes required by law, to disclose your health information in the course of any administrative or judicial proceeding to the extent expressly authorized by a court or administrative order. We may also disclose information about you in response to a subpoena, discovery request or other lawful process if reasonable efforts have been made to notify you of the request and you have not objected, or if your objections have been resolved by a court or administrative order. Law Enforcement-We may, and are sometimes required by law, to disclose your health information to a law enforcement official for purposes such as identifying or locating a suspect, fugitive, material witness or missing person, complying with a court order, warrant, grand jury subpoena and other law enforcement purposes. Coroners-We may, and are often required by law, to disclose your health information to coroners in connection with their investigations of deaths. Public Safety-We may, and are sometimes required by law, to disclose your health information to appropriate persons in order to prevent or lessen a serious and imminent threat to the health or safety of a particular person or the general public. Specialized Government Functions-We may disclose your health information for military or national security purposes or to correctional institutions or law enforcement officers that have you in their lawful custody. Change of Ownership-In the event that this medical practice is sold or merged with another organization, your health information/record will become the property of the new owner, although you will maintain the right to request that copies of your health information be transferred to another physician or medical group. Breach Notification. In the case of a breach of unsecured protected health information, we will notify you as required by law. If you have provided us with a current address, we may use to communicate information related to the breach. In some circumstances our business associate may provide the notification. We may also provide notification by other methods as appropriate. Psychotherapy Notes-We will not use or disclose your psychotherapy notes without your prior written authorization except for the following: 1) use by the originator of the notes for your treatment, 2) for training our staff, students and other trainees, 3) to defend ourselves if you sue us or bring some other legal proceeding, 4) if the law requires us to disclose the information to you or the Secretary of HHS or for some other reason, 5) in response to health oversight activities concerning your psychotherapist, 6) to avert a serious and imminent threat to health or safety, or 7) to the coroner or medical examiner after you die. To the extent you revoke an authorization to use or disclose your psychotherapy notes, we will stop using or disclosing these notes.

8 Research- We may disclose your health information to researchers conducting research with respect to which your written authorization is not required as approved by an Institutional Review Board or privacy board, in compliance with governing law. You re Health Information Rights: Right to Request Special Privacy Protections-You have the right to request restrictions on certain uses and disclosures of your health information by a written request specifying what information you want to limit, and what limitations on our use or disclosure of that information you wish to have imposed. If you tell us not to disclose information to your commercial health plan concerning health care items or services for which you paid for in full out-of-pocket, we will abide by your request, unless we must disclose the information for treatment or legal reasons. We reserve the right to accept or reject any other request, and will notify you of our decision. Right to Request Confidential Communications- You have the right to request that you receive your health information in a specific way or at a specific location. For example, you may ask that we send information to a particular account or to your work address. We will comply with all reasonable requests submitted in writing which specify how or where you wish to receive these communications. Right to Inspect and Copy- You have the right to inspect and copy your health information, with limited exceptions. To access your medical information, you must submit a written request detailing what information you want access to, whether you want to inspect it or get a copy of it, and if you want a copy, your preferred form and format. We will provide copies in your requested form and format if it is readily producible, or we will provide you with an alternative format you find acceptable, or if we can't agree and we maintain the record in an electronic format, your choice of a readable electronic or hardcopy format. We will also send a copy to any other person you designate in writing. We will charge a reasonable fee which covers our costs for labor, supplies, postage, and if requested and agreed to in advance, the cost of preparing an explanation or summary. We may deny your request under limited circumstances. If we deny your request to access your child's records or the records of an incapacitated adult you are representing because we believe allowing access would be reasonably likely to cause substantial harm to the patient, you will have a right to appeal our decision. If we deny your request to access your psychotherapy notes, you will have the right to have them transferred to another mental health professional. Right to Amend or Supplement- You have a right to request that we amend your health information that you believe is incorrect or incomplete. You must make a request to amend in writing, and include the reasons you believe the information is inaccurate or incomplete. We are not required to change your health information, and will provide you with information about this medical practice's denial and how you can disagree with the denial. We may deny your request if we do not have the information, if we did not create the information (unless the person or entity that created the information is no longer available to make the amendment), if you would not be permitted to inspect or copy the information at issue, or if the information is accurate and complete as is. If we deny your request, you may submit a written statement of your disagreement with that decision, and we may, in tum, prepare a written rebuttal. All information related to any request to amend will be maintained and disclosed in conjunction with any subsequent disclosure of the disputed information.

9 Right to an Accounting of Disclosures. You have a right to receive an accounting of disclosures of your health information made by this medical practice, except that this medical practice does not have to account for the disclosures provided to you or pursuant to your written authorization, or as described in paragraphs 1 (treatment), 2 (payment), 3 (health care operations), 6 (notification and communication with family) and 18 (specialized government functions) of Section A of this Notice of Privacy Practices or disclosures for purposes of research or public health which exclude direct patient identifiers, or which are incident to a use or disclosure otherwise prohibited or authorized by law, or the disclosures to a health oversight agency or law enforcement official to the extent this medical practice has received notice from that agency or official that providing this accounting would be reasonably likely to impede their activities. Right to a Paper or Electronic Copy of this Notice- You have a right to notice of our legal duties and privacy practices with respect to your health information, including a right to a paper copy of this Notice of Privacy Practices, even if you have previously requested its receipt by-mail. Except as described in this Notice of Privacy Practices, this medical practice will, consistent with its legal obligations, not use or disclose health information which identifies you without your written authorization. If you do authorize this medical practice to use or disclose your health information for another purpose, you may revoke your authorization in writing at any time. Complaints about this Notice of Privacy Practices or how this medical practice handles your health information should be directed to our Privacy Officer: Steve Nicola, privacy officer for ReNu Chattanooga (423) If you are not satisfied with the manner in which this office handles a complaint, you may submit a formal complaint to: TN Secretary of Health & Human Services at address 311 M L King Blvd, Chattanooga, TN You may find a complaint form at: You will not be penalized in any way for filing a complaint.

10 PAULA NICOLA, M.D. ERLANGER MEDICAL MALL 979 EAST THIRD STREET. SUITE 240 CHATTANOOGA, TN PHONE FAX Explanation of First Visit/Induction Your first visit is generally the longest, and may last anywhere from 1 to 4 hours. When preparing for your first office visit, there are a couple of logistical issues you may want to consider: You may not be able to return to work/begin work shift following your visit this is very normal so just plan accordingly Because the medication can cause drowsiness and slow reaction times, particularly during the first few weeks of treatment, you may want to make arrangements for a ride home It is very important to arrive for your first visit already experiencing moderate opioid withdrawal symptoms. If you are in withdrawal, the medicine is supposed to help lessen the symptoms. However, if you are not in withdrawal, the medicine will override the opioids already in your system, which will cause severe withdrawal symptoms. The following guidelines are provided to ensure you are in withdrawal for the visit. If this concerns you, it may help to schedule your first visit in the morning; some patients find it easiest to skip what would normally be their first dose of the day. No methadone or long-acting painkillers for at least 24 hours. No heroin or short-acting painkillers for at least 4 to 6 hours Bring ALL medication bottles with you to your first appointment. Before you can be seen by the doctor, all of the paperwork your doctor provided must be completed. If your doctor provided the paperwork to you prior to this visit, bring it completed or arrive about 30 minutes early to fill it out. Urine drug screening is a regular procedure of treatment, because it provides physicians with important insights into your health and your treatment. Your first visit will include urine drug screening and may also entail blood work. If you haven t had a recent physical exam, your doctor may require one. To help ensure that this medicine is the best treatment option for you, your doctor will perform a substance dependence assessment and mental status evaluation. Lastly, you and your doctor will discuss the medicine and your expectations of treatment. After this portion of your visit is completed, your doctor will administer your first dose. Your doctor will have you the fill the prescription they provide you at this appointment at the pharmacy and return to the doctor s office so you can take the medication under observation. Once you take your first dose, you should begin to feel better within 30 minutes. Your doctor may choose to give you additional doses while you are in the office. It s important that you are honest about how you are feeling during induction so your doctor can find the appropriate dose for you. When you leave the office, the doctor will likely give you a prescription that will last until your next appointment. The doctor may also want to discuss counseling with you, since medication plus counseling has been shown to produce better results. At the same time, your doctor may suggest enrolling in the Here to Help Program, which can provide you with an added support system.

11 Your doctor may ask you to keep a record of any medications you take at home to control withdrawal symptoms. You will also receive instructions on how to contact your doctor in emergency, as well as additional information about treatment. Your Checklist for Your First Visit at ReNu Chattanooga: Arrive experiencing moderate opioid withdrawal symptoms Arrive prepared to give a urine sample for screening Bring completed forms (or come 30 minutes early) Bring ALL medication bottles Bring all fees due at time of visit (cash or credit card only) Please see your doctor or pharmacist for full product information for your medicine.

12 PAULA NICOLA, M.D. ERLANGER MEDICAL MALL 979 EAST THIRD STREET. SUITE 240 CHATTANOOGA, TN PHONE FAX Consent to Treatment with Buprenorphine Suboxone (a tablet with buprenorphine and naloxone) is an FDA-approved medication for treatment of people with opioid or heroin addiction. Buprenorphine can be used for detoxification or for maintenance therapy. Maintenance therapy can continue as long as medically necessary. There are other treatments for opiate addiction, including methadone, and some treatments without medications that include counseling, groups and meetings. If you are dependent on opiates any opiates you should be in as much withdrawal as possible when you take the first dose of buprenorphine. If you are not in withdrawal, buprenorphine can cause severe opiate withdrawal. For that reason, you should take the first dose in the office and remain in the office for at least an hour. We recommend that you arrange not to drive after your first dose, because some patients get drowsy until the correct dose is determined for them. Some patients find that it takes several days to get used to the transition from the opiate they had been using to buprenorphine. During that time, any use of other opiates may cause an increase in symptoms. After you become stabilized on buprenorphine, it is expected that other opiates will have less effect. Attempts to override the buprenorphine by taking more opiates could result in an opioid overdose. You should not take any other medication without discussing it with Dr. Nicola first. Combining buprenorphine with alcohol or other sedating medications is dangerous. The combination of buprenorphine with benzodiazepines (such as Valium, Librium, Ativan, Xanax, Klonopin, etc.) has resulted in deaths. The form of buprenorphine (Suboxone) you will be taking is a combination of buprenorphine with a short-acting opiate blocker (Naloxone). It will maintain physical dependence, and if you discontinue it suddenly you will likely experience withdrawal. If you are not already dependent, you should not take buprenorphine, since it could eventually cause physical dependence. Buprenorphine strips must be held under the tongue until they dissolve completely. It is important not to talk or swallow until the strip dissolves. This takes up to ten minutes. Buprenorphine is then absorbed over the next 30 to 120 minutes from the tissue under the tongue. Buprenorphine will not be absorbed from the stomach if it is swallowed. If you swallow the strip, you will not have the important benefits of the medication, and it may not relieve your withdrawal. Most patients end up at a daily dose of 12 mg to 24 mg of buprenorphine (this is roughly equivalent to 60 mg of methadone maintenance). Beyond that dose, the effects of buprenorphine plateau, so there may not be any more benefit to an increase in dose. It may take several weeks to determine just the right dose for you. The first dose is usually 8 mg and will be given in the office. If you are transferring to Suboxone from methadone maintenance, your dose has to be tapered until you have been below 30 mg for at least a week. There must be at least 24 hours (preferably longer) between the time you take your last methadone dose and the time you are given your first dose of buprenorphine. On the day of induction onto buprenorphine, you should come to the office already in opiate withdrawal. The day before induction, you must not have used any opiate (heroin, methadone, codeine, or other opiate-containing medications). If there are not observable signs of opiate withdrawal, my induction onto buprenorphine may be delayed a day or more. I understand that take home doses and frequency of visits will be determined by how well I am doing, but will be at least monthly.

13 I understand that the goal of treatment of opiate dependency is to learn to live without abuse of drugs. Buprenorphine treatment will be continued as long as necessary to prevent relapse to opiate abuse/dependence. I understand that I cannot drive motor vehicles or use power tools or other dangerous machinery during my first days of taking buprenorphine, to make sure that I can tolerate taking it without becoming sleepy or clumsy as a side effect of taking it. I understand the need to be open and honest with Dr. Nicola and the staff at ReNu Chattanooga regarding my cravings, my potential to relapse to the extent that I am aware of such, and specifically about any relapses which have occurred before a drug test result shows it. For women only: The safety of taking Suboxone during pregnancy is unknown. I am not pregnant, and I will not attempt to become pregnant while taking Suboxone. I agree to not have unprotected sex while I am taking buprenorphine. I agree to tell my physician if I become pregnant or even think I may be pregnant. I understand that Dr. Nicola will likely discontinue Suboxone treatment if I become pregnant or may consider a switch to Subutex therapy upon consultation with a high risk obstetrician. I have read and understand these details about buprenorphine treatment. I wish to be treated with buprenorphine. Patient Signature: Date: Physician Signature: Date:

14 ReNu Chattanooga Paula C. Nicola, MD 979 East Third Street, STE A240 Chattanooga, TN Phone (423) Fax (423) AUTHORIZATION TO RELEASE HEALTHCARE INFORMATION Patient s Name: Date of Birth: Social Security # I request and authorize to release healthcare information of the patient named above to: Name: Address: This request and authorization applies to : Healthcare information relating to the following treatment, condition, or dates: All healthcare information Other: I authorize the release of any records regarding drug, alcohol, or mental health treatment to the person(s) listed above. Yes No Patient Signature: Date Signed: **This authorization will expire one year form date signed unless a written request is received to revoke this authorization prior to the expiration date**

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone PATIENT INTAKE: MEDICAL HISTORY Name Address Phone (W) (H) (C) DOB Age SS# Emergency Contact Relationship to patient Phone Primary care physician Phone Have you ever had an EKG? Y N Date Current or past

More information

SUBOXONE FILM NEW PATIENT INTRODUCTION

SUBOXONE FILM NEW PATIENT INTRODUCTION SUBOXONE FILM NEW PATIENT INTRODUCTION Our clinic restricts our treatment panel to a limited number of pre-qualified patients. This program accepts only patients who are serious about overcoming opiate

More information

COMPASS RECOVERY OPIOID REHABILITATION PROGRAM QUESTIONAIRE FOR PROSPECTIVE OPIOID REHABILITATION. Name Birthdate / /

COMPASS RECOVERY OPIOID REHABILITATION PROGRAM QUESTIONAIRE FOR PROSPECTIVE OPIOID REHABILITATION. Name Birthdate / / COMPASS RECOVERY OPIOID REHABILITATION PROGRAM QUESTIONAIRE FOR PROSPECTIVE OPIOID REHABILITATION Name Birthdate / / Home phone ( ) - Cell phone ( ) - Please answer the following questions which will help

More information

PATIENT TREATMENT CONTRACT

PATIENT TREATMENT CONTRACT Bridger Psychiatric Services, P.C. 2040 N. 22 nd Avenue, Ste. 2 Bozeman, MT 59718 406-586-5511 * 406-586-4713 (fax) PATIENT TREATMENT CONTRACT Patient Name Date As a participant in buprenorphine treatment

More information

Patient Agreement for the use of Opioid Medications

Patient Agreement for the use of Opioid Medications today s date Patient Name date of birth Patient Agreement for the use of Opioid Medications The purpose of this agreement is to give you information about the medications that may be part of your treatment

More information

COMMUNITY HOSPICE & PALLIATIVE CARE NOTICE OF PRIVACY PRACTICES

COMMUNITY HOSPICE & PALLIATIVE CARE NOTICE OF PRIVACY PRACTICES COMMUNITY HOSPICE & PALLIATIVE CARE NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE

More information

19 TH JUDICIAL DUI COURT REFERRAL INFORMATION

19 TH JUDICIAL DUI COURT REFERRAL INFORMATION 19 TH JUDICIAL DUI COURT REFERRAL INFORMATION Please review the attached DUI Court contract and Release of Information. ******* You must sign and hand back to the court the Release of Information today.

More information

PATIENT SIGNATURE: DOB: Date:

PATIENT SIGNATURE: DOB: Date: CINCINNATI PAIN PHYSICIANS, LLC (CPP) ACKNOWLEDGEMENT OF RECEIPT OF NOTICE OF PRIVACY PRACTICES By signing below, I acknowledge that I have received a copy of CPP s Notice of Privacy Practices. The Notice

More information

WELD COUNTY ADULT TREATMENT COURT REFERRAL INFORMATION

WELD COUNTY ADULT TREATMENT COURT REFERRAL INFORMATION WELD COUNTY ADULT TREATMENT COURT REFERRAL INFORMATION Please review the attached Adult Treatment Court contract and Authorization to Share Information. Once your case has been set on the adult treatment

More information

Initial Clinical History and Physical Form

Initial Clinical History and Physical Form 601 E FM 544, Suite 400, Murphy, TX, 75094 TEL: 972-442-4700 Initial Clinical History and Physical Form Patient Information Name: Age: of Birth: / / Sex: Male / Female Marital Status: Single Married Divorced

More information

Ahsan U. Rashid, M.D., F.A.C.P.

Ahsan U. Rashid, M.D., F.A.C.P. Ahsan U. Rashid, M.D., F.A.C.P. OPIOID MAINTENANCE AND CONSENT Instructions: Review this document before signing. This document will help both the patient and caregivers in establishing a medical program

More information

DELTA DENTAL PREMIER

DELTA DENTAL PREMIER DELTA DENTAL PREMIER PARTICIPATING DENTIST AGREEMENT THIS AGREEMENT made and entered into this day of, 20 by and between Colorado Dental Service, Inc. d/b/a Delta Dental of Colorado, as first party, hereinafter

More information

Patient and Family Agreement on Opioids

Patient and Family Agreement on Opioids Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from

More information

METROLINX ADMINISTRATIVE FEE DISPUTE RESOLUTION PROCESS RULES OF PRACTICE

METROLINX ADMINISTRATIVE FEE DISPUTE RESOLUTION PROCESS RULES OF PRACTICE METROLINX ADMINISTRATIVE FEE DISPUTE RESOLUTION PROCESS RULES OF PRACTICE Overview The Metrolinx Act, 2006, gives Metrolinx ( Metrolinx ) the authority to establish a system of administrative fees to ensure

More information

MEDICATION MANAGEMENT AGREEMENT

MEDICATION MANAGEMENT AGREEMENT MEDICATION MANAGEMENT AGREEMENT The goal of this agreement is to ensure that you and your physician comply with all state and federal regulations concerning the prescribing of controlled substances. The

More information

If you do not have health insurance, the initial appointment will be $232. Follow-up appointments will be $104.

If you do not have health insurance, the initial appointment will be $232. Follow-up appointments will be $104. APPLICATION FOR ADMISSION TO ADDICTION MEDICINE PROGRAM AT MARQUETTE GENERAL BEHAVIORAL HEALTH SERVICES FOR BUPRENORPHINE (Suboxone) THERAPY In order to be considered for admission to the Addiction Medicine

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

FREQUENTLY ASKED QUESTIONS PATIENTS SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate) sublingual tablet

FREQUENTLY ASKED QUESTIONS PATIENTS SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate) sublingual tablet 463142 State Road 200, Yulee, Florida 32097 Phone: 904-225-8280 Fax: 904-225-8232 FREQUENTLY ASKED QUESTIONS PATIENTS SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate) sublingual tablet 1. Why do I have

More information

Methadone/ Suboxone Treatment in federal prison

Methadone/ Suboxone Treatment in federal prison INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone/ Suboxone Treatment in federal prison This booklet will explain how to qualify for Opioid Substitution Therapy (OST) in prison, how it is

More information

Informed Consent for MINDFULNESS BASED Cognitive Therapy

Informed Consent for MINDFULNESS BASED Cognitive Therapy Informed Consent for MINDFULNESS BASED Cognitive Therapy The state expects that you will be informed of all possible contingencies that might arise in the course of short - and long-term therapy. Please

More information

ADDICTION SERVICES New Patient Paperwork To be completed by Patient PLEASE PRINT and take your time to fill out completely

ADDICTION SERVICES New Patient Paperwork To be completed by Patient PLEASE PRINT and take your time to fill out completely ADDICTION SERVICES New Patient Paperwork To be completed by Patient PLEASE PRINT and take your time to fill out completely Name: Sex: ( ) Male ( )Female Address: Phone (Home) (Cell) (Other) D.O.B. Age

More information

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers

More information

Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee Phone:

Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee Phone: Washington County-Johnson City Health Department Christen Minnick, MPH, Director 219 Princeton Road Johnson City, Tennessee 37601 Phone: 423-975-2200 Dear Parent: The Washington County Health Department

More information

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine The purpose of this agreement is to give you information about the medications you will be taking for

More information

Appendix F Federation of State Medical Boards

Appendix F Federation of State Medical Boards Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction

More information

Effective Date: 9/14/06 NOTICE PRIVACY RULES FOR VALUEOPTIONS

Effective Date: 9/14/06 NOTICE PRIVACY RULES FOR VALUEOPTIONS Effective Date: 9/14/06 NOTICE PRIVACY RULES FOR VALUEOPTIONS This notice describes how medical information about you may be used and disclosed and how you can get access to this information. If you have

More information

Medical gap arrangements - practitioner application

Medical gap arrangements - practitioner application Medical gap arrangements - practitioner application For services provided in a licensed private hospital or day hospital facility (Private Hospital) only. Please complete this form to apply for participation

More information

Effective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use

Effective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use Effective Date: May 19, 2008 Revised Date: August 18, 2015 Approved by: Thomas M Tocher, MD, MPH, Chief Clinical Officer Policy Number: MED Policy 313 Title: Pain Management Long Term Opioid Use POLICY

More information

E. "Prospective employee": A person who has made application, whether written or oral, to CWI to become an employee.

E. Prospective employee: A person who has made application, whether written or oral, to CWI to become an employee. POLICY FOR A DRUG AND ALCOHOL-FREE WORKPLACE I. STATEMENT OF PURPOSE Crossroads of Western Iowa recognizes the problems of substance abuse in society and in the workplace. Substance abuse poses a serious

More information

Workplace Drug and Alcohol Policy

Workplace Drug and Alcohol Policy Workplace Drug and Alcohol Policy January 2017 This Drug and Alcohol Policy is intended for and includes but is not limited to all Students, Contractors and all others either directly or indirectly engaged

More information

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New

More information

NOTICE OF APPEAL OR PETITION

NOTICE OF APPEAL OR PETITION NOTICE OF APPEAL OR PETITION State Personnel Board 801 Capitol Mall Sacramento, CA 95814 Dismissal Demotion Suspension ( days) Medical Demotion / Termination Automatic Resignation (AWOL) Set Aside Resignation

More information

Methadone Treatment. in federal prison

Methadone Treatment. in federal prison INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional

More information

For female patients only: To the best of my knowledgei am NOT pregnant. Patients Initials:

For female patients only: To the best of my knowledgei am NOT pregnant. Patients Initials: Which doctor are you here to see? NAME OF PATIENT: DATE: TO THE PATIENT: As a patient, you have the right to be informed about your condition and the recommended medical or diagnostic procedure or drug

More information

RPSGT Recertification Application

RPSGT Recertification Application RPSGT Recertification Application RPSGT: RESPECTED WORLDWIDE AS THE LEADING CREDENTIAL FOR POLYSOMNOGRAPHIC TECHNOLOGISTS Please be sure to read the BRPT Recertification Guidelines located at www.brpt.org

More information

Medications. New Patient Registration. Billing and Insurance. Phone Calls. Prescription Refills. Lab Results and Test Results

Medications. New Patient Registration. Billing and Insurance. Phone Calls. Prescription Refills. Lab Results and Test Results Dear New Patient: We would like to welcome you to our practice. Our goal is to make your experience with us as pleasant as possible. In order to help us meet this goal we have listed some helpful hints

More information

Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain

Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain Department of Veterans Affairs (VA) and Department of Defense

More information

Exhibit 2 RFQ Engagement Letter

Exhibit 2 RFQ Engagement Letter Exhibit 2 RFQ 17-25 Engagement Letter The attached includes the 6 page proposed engagement letter to be used by HCC. ENGAGEMENT LETTER Dear: [Lead Counsel/Partner] We are pleased to inform you that your

More information

Methadone Treatment. in federal prison

Methadone Treatment. in federal prison INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional

More information

Adult Audiology Intake Form

Adult Audiology Intake Form Harry Jersig Center 411 S.W. 24 th Street San Antonio, TX 78207 (210) 431-3938 Adult Audiology Intake Form Identifying Information Name: Address: Last First Middle No. & Street City State Zipcode Date

More information

DRUG FREE WORKPLACE POLICY

DRUG FREE WORKPLACE POLICY GENERAL STATEMENT DRUG FREE WORKPLACE POLICY Kitsap County Government is obligated and committed to provide our employees and the citizens of Kitsap County with an alcohol and drug free, healthy, safe,

More information

COMPLETE DRUG AND ALCOHOL POLICY & Testing Policy

COMPLETE DRUG AND ALCOHOL POLICY & Testing Policy COMPLETE DRUG AND ALCOHOL POLICY & Testing Policy... Rev 12/2012 1 I. STATEMENT OF POLICY Robért Resources LLC. ( Robért s ) and it s related companies is committed to providing safe, healthful, and efficient

More information

Welcome to Our Office!

Welcome to Our Office! Welcome to Our Office! We would like to take the time to Thank You for allowing us to take great care of you and provide you with excellent dental care. Please take a moment to tell us how you heard about

More information

Practice Welcome Letter (REVISED )

Practice Welcome Letter (REVISED ) Practice Welcome Letter (REVISED 7-1-2014) Dear Patient: WELCOME TO OVER THE RAINBOW COUNSELING! This letter serves to introduce myself, Cynthia Denise Porter, as your therapist. In choosing a mental health

More information

CDL Drivers Controlled Substance and Alcohol Policy

CDL Drivers Controlled Substance and Alcohol Policy CDL Drivers Controlled Substance and Alcohol Policy Section 1. General. It is the purpose of this policy to encourage an enlightened viewpoint toward alcoholism and other drug dependencies as behavioral/medical

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Drug and Alcohol Policy

Drug and Alcohol Policy Drug and Alcohol Policy Purpose Skillset Pty Ltd ( Skillset ) is committed to providing a safe and healthy work environment, so far as is reasonably practicable in which all workers are treated fairly,

More information

Patient Application for Treatment

Patient Application for Treatment Address: 179 Linwood Ave. Colchester, CT 06415 Phone: (860) 603-3541 Fax: (860) 603-3544 Visit Date: / / MR#: Patient Application for Treatment 1. Name: 2. Date of Birth: 3. Social Security #: 2. Address:

More information

PSYCHOLOGIST-PATIENT SERVICES

PSYCHOLOGIST-PATIENT SERVICES PSYCHOLOGIST-PATIENT SERVICES PSYCHOLOGICAL SERVICES Welcome to my practice. Because you will be putting a good deal of time and energy into therapy, you should choose a psychologist carefully. I strongly

More information

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

On December 27, 2017, the Lieutenant Governor signed into law several new requirements OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following

More information

OPIOID PAIN MEDICATION Agreement and Informed Consent

OPIOID PAIN MEDICATION Agreement and Informed Consent OPIOID PAIN MEDICATION Agreement and Informed Consent I. Introduction Research and clinical experience show that opioid (narcotic) pain medications are helpful for some patients with chronic pain. The

More information

OUTPATIENT SERVICES PSYCHOLOGICAL SERVICES CONTRACT

OUTPATIENT SERVICES PSYCHOLOGICAL SERVICES CONTRACT OUTPATIENT SERVICES PSYCHOLOGICAL SERVICES CONTRACT (This is a detailed document. Please feel free to read at your leisure and discuss with Dr. Gard in subsequent sessions. It is a document to review over

More information

SUBOXONE TREATMENT PROGRAM

SUBOXONE TREATMENT PROGRAM SUBOXONE TREATMENT PROGRAM What is Suboxone? Suboxone is a medication used for the treatment of addiction to prescription pain medication, heroin addiction, methadone or other opioid dependence. The primary

More information

Notice of Procedural Safeguards. October

Notice of Procedural Safeguards. October Notice of Procedural Safeguards 2014 October Rights of Parents of Children with Disabilities The Individuals with Disabilities Education Act (IDEA), as amended in 2004, requires schools to provide parents

More information

Personal Disclosure Statement and Notice of Practices

Personal Disclosure Statement and Notice of Practices Sound Therapy of Seattle Lisa Gormley-Leinster, M.A., LMHC, NCC, CCMHC 200 1st Ave West, Seattle, WA 98119 Phone: (206) 659-1738 www.soundtherapyofseattle.com soundtherapyofseattle@gamil.com Personal Disclosure

More information

New patients approved for the Novo Nordisk PAP may only be eligible for insulin vials. For a full list of available products, please visit:

New patients approved for the Novo Nordisk PAP may only be eligible for insulin vials. For a full list of available products, please visit: The Novo Nordisk Diabetes Patient Assistance Program (PAP) provides medication to qualifying applicants at no charge. If the applicant qualifies under the Novo Nordisk Diabetes PAP guidelines, a 120-day

More information

Address (if different from above):

Address (if different from above): Lee H. Baker, DDS 1243 Augusta West Pkwy Augusta, GA 30909 (706) 855-8989-Phone (706) 855-0321-Fax www.drleebaker.com Welcome to our practice! In order to know you and your child better, please complete

More information

Buprenorphine & Controlled Substance Treatment Agreement

Buprenorphine & Controlled Substance Treatment Agreement Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a

More information

Substance Abuse Policy. Substance Abuse Policy for Employees and Students

Substance Abuse Policy. Substance Abuse Policy for Employees and Students College Rules and Regulations 2.2008.1 Substance Abuse Policy Substance Abuse Policy for Employees and Students I. Substance Abuse Policy for Employees and Students A. Purpose The County College of Morris

More information

Kenosha County Drug and Alcohol Abuse Policy

Kenosha County Drug and Alcohol Abuse Policy Kenosha County Drug and Alcohol Abuse Policy Kenosha County is committed to protecting the safety, health and well-being of all employees and other individuals in our workplace. We recognize that alcohol

More information

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent Pain may be effectively managed through the use of controlled substance medications (referred to below as opioids

More information

Termination: Ending the Therapeutic Relationship-Avoiding Abandonment

Termination: Ending the Therapeutic Relationship-Avoiding Abandonment Termination: Ending the Therapeutic Relationship-Avoiding Abandonment By Elizabeth M. Felton, JD, LICSW, Associate Counsel and Carolyn I. Polowy, JD, General Counsel March 2015. National Association of

More information

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone) 9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

NEW PATIENT PAPERWORK

NEW PATIENT PAPERWORK NEW PATIENT PAPERWORK Welcome! Please fill out the necessary paperwork provided. It is our pleasure to serve you and your family. How did you find out about us? If It was a friend or doctor, please list

More information

SOUTHSIDE COMMUNITY ACUPUNCTURE, LLC. Financial Policies

SOUTHSIDE COMMUNITY ACUPUNCTURE, LLC. Financial Policies Disclosure of Information - Please Read the Following Carefully How to Prepare for Your First Visit : Plan on showing up a 15 minutes early to your first appointment and please wear, or bring with you

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. 201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. RELATES TO: KRS 311.530-311.620, 311.990 STATUTORY AUTHORITY: KRS

More information

Access Endodontics Marat Tselnik, DDS -PRACTICE LIMITED TO ENDODONTICS-

Access Endodontics Marat Tselnik, DDS -PRACTICE LIMITED TO ENDODONTICS- Access Endodontics Marat Tselnik, DDS -PRACTICE LIMITED TO ENDODONTICS- REFERRED BY: TODAY S DATE: PATIENT NAME HOME PHONE (LAST) (FIRST) (MIDDLE) E-MAIL CELL PHONE HOME ADDRESS (STREET) (CITY) (STATE)

More information

APPLICATION FOR ADMISSION (PLEASE PRINT CLEARLY)

APPLICATION FOR ADMISSION (PLEASE PRINT CLEARLY) 1317 w. Washington Blvd. Fort Wayne, In. 46802 260-424-2341 APPLICATION FOR ADMISSION (PLEASE PRINT CLEARLY) NAME: _ FIRST MI LAST DATE OF BIRTH: / / AGE: SOCIAL SECURITY NUMBER: LAST OR CURRENT ADDRESS:

More information

Florida A & M University Office of Human Resources INTERNAL OPERATING PROCEDURE. Procedure No. HR-7000

Florida A & M University Office of Human Resources INTERNAL OPERATING PROCEDURE. Procedure No. HR-7000 Subject: Alcohol and Drug Testing Policy Florida A & M University Office of Human Resources INTERNAL OPERATING PROCEDURE Procedure No. HR-7000 Authority: Florida Statutes 1001.74; Chapter 112.0455, Florida

More information

Patient Information Form

Patient Information Form Patient Information Form Patient Name: (Last) (First) (MI) Name you prefer to be called: Mailing address: City: State: Zip: Best daytime phone: May we leave a message there? Yes No Alternate phone number:

More information

(4) Be as detailed as necessary to provide history of work performed; and:

(4) Be as detailed as necessary to provide history of work performed; and: www.omarfigueroa.com Page 66 of 278 (4) Be as detailed as necessary to provide history of work performed; and: (A) Include information adequate to identify any associated manufacturing facility (e.g.,

More information

DRUG-FREE AND ALCOHOL-FREE WORK PLACE

DRUG-FREE AND ALCOHOL-FREE WORK PLACE DRUG-FREE AND ALCOHOL-FREE WORK PLACE The following applies to all employees: 1. The Gloucester County Public School System has a vital interest in maintaining a safe, healthy, and productive environment

More information

Z E N I T H M E D I C A L P R O V I D E R N E T W O R K P O L I C Y Title: Provider Appeal of Network Exclusion Policy

Z E N I T H M E D I C A L P R O V I D E R N E T W O R K P O L I C Y Title: Provider Appeal of Network Exclusion Policy TheZenith's Z E N I T H M E D I C A L P R O V I D E R N E T W O R K P O L I C Y Title: Provider Appeal of Network Exclusion Policy Application: Zenith Insurance Company and Wholly Owned Subsidiaries Policy

More information

The CARA & Buprenorphine Prescribing for APNs & PAs

The CARA & Buprenorphine Prescribing for APNs & PAs The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,

More information

Wilson C, Fagan E. Providing office-based treatment of opioid use disorder. Ann Fam Med. 2017;15(5):481.

Wilson C, Fagan E. Providing office-based treatment of opioid use disorder. Ann Fam Med. 2017;15(5):481. Supplemental material for Wilson C, Fagan E. Providing office-based treatment of opioid use disorder. Ann Fam Med. 2017;15(5):481. Courtenay Gilmore Wilson, PharmD 1,2 E. Blake Fagan, MD 1,3 1 Mountain

More information

PATIENT HISTORY DATA FORM Psychiatric, Health and Wellness, LLC 810 Michael Drive, Suite L Chesterton, IN NAME

PATIENT HISTORY DATA FORM Psychiatric, Health and Wellness, LLC 810 Michael Drive, Suite L Chesterton, IN NAME PATIENT HISTORY DATA FORM Psychiatric, Health and Wellness, LLC 810 Michael Drive, Suite L Chesterton, IN 46304 PRINT THIS FORM, COMPLETE AND BRING WITH YOU (DO NOT COMPLETE ONLINE) : NAME: LAST FIRST

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

Confirm Limit--Level of detectable drugs in urine to confirm a positive test.

Confirm Limit--Level of detectable drugs in urine to confirm a positive test. Alcohol and Substance Abuse Policy Purpose To establish and maintain a safe, healthy working environment for all PVFD members; reduce the incidence of accidental injury to members and property; reduce

More information

DRUG AND ALCOHOL POLICY

DRUG AND ALCOHOL POLICY DRUG AND ALCOHOL POLICY I. Policy Section: 6.0 Human Resources II. Policy Subsection: 6.24 Drug and Alcohol Policy III. Policy Statement Grand Rapids Community College is committed to the elimination of

More information

CLINTON-ESSEX-WARREN-WASHINGTON BOCES Drug and Alcohol Testing. Champlain Valley Educational Services P.O. Box 455 Plattsburgh, NY

CLINTON-ESSEX-WARREN-WASHINGTON BOCES Drug and Alcohol Testing. Champlain Valley Educational Services P.O. Box 455 Plattsburgh, NY CLINTON-ESSEX-WARREN-WASHINGTON BOCES 9095 Drug and Alcohol Testing Champlain Valley Educational Services P.O. Box 455 Plattsburgh, NY 12901-0455 TABLE OF CONTENTS Drug and Alcohol Testing... 3 A. Purpose...

More information

EMPLOYEE RELATIONS POLICY NO. 512

EMPLOYEE RELATIONS POLICY NO. 512 Beartooth Electric Cooperative, Inc. EMPLOYEE RELATIONS POLICY NO. 512 1. SUBJECT: ALCOHOL AND DRUG FREE WORKPLACE - DOT 2. PURPOSE: 2.1. Beartooth Electric Cooperative, Inc. (BEC) is committed to employee

More information

DEKALB COUNTY GOVERNMENT DRUG-FREE WORKPLACE POLICY

DEKALB COUNTY GOVERNMENT DRUG-FREE WORKPLACE POLICY DEKALB COUNTY GOVERNMENT DRUG-FREE WORKPLACE POLICY Reviewed For Updates March 1, 2017 DeKalb County Government Drug-Free Workplace Policy CURRENT DATE OF CONTENTS OF DRUG-FREE WORKPLACE POLICY Pg. Section

More information

State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education

State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education Introduction Steps to Protect a Child s Right to Special Education: Procedural

More information

OREGON MEDICAL MARIJUANA ACT

OREGON MEDICAL MARIJUANA ACT OREGON MEDICAL MARIJUANA ACT 475.300 Findings. The people of the state of Oregon hereby find that: (1) Patients and doctors have found marijuana to be an effective treatment for suffering caused by debilitating

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental

More information

Certification in Lower Extremity Geriatric Medicine Handbook

Certification in Lower Extremity Geriatric Medicine Handbook Certification in Lower Extremity Geriatric Medicine Handbook 555 8 th Ave, Ste 1902, New York, NY 10018 888 852 1442 1 Mission Statement We exist to protect and improve the podiatric health and welfare

More information

Alcohol & Drug Practice

Alcohol & Drug Practice Alcohol & Drug Practice Vice-President, Health & Safety June 1, 2011 Purpose Cenovus recognizes that the use of alcohol and drugs can adversely affect job performance, the work environment and the safety

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency

More information

ADULT INTAKE QUESTIONNAIRE. Ok to leave message? Yes No. Present psychological difficulties please check any that apply to you at this time.

ADULT INTAKE QUESTIONNAIRE. Ok to leave message? Yes No. Present psychological difficulties please check any that apply to you at this time. ADULT INTAKE QUESTIONNAIRE Name: Today s Date: Age: Date of Birth: Address: Home phone: Work phone: Cell phone: Ok to leave message? Yes No Ok to leave message? Yes No Ok to leave message? Yes No Email:

More information

Act 443 of 2009 House Bill 1379

Act 443 of 2009 House Bill 1379 Act 443 of 2009 House Bill 1379 AN ACT TO PROVIDE FOR THE LICENSURE OF ALCOHOLISM AND DRUG ABUSE COUNSELORS; TO PROVIDE FOR THE REGISTRATION OF CLINICAL ALCOHOLISM AND DRUG ABUSE COUNSELOR SUPERVISORS;

More information

DISCLOSURE OF ALCOHOL AND SUBSTANCE/DRUG ABUSE RECORDS. This Policy describes permissible disclosures of Alcohol and Substance/Drug Abuse Records.

DISCLOSURE OF ALCOHOL AND SUBSTANCE/DRUG ABUSE RECORDS. This Policy describes permissible disclosures of Alcohol and Substance/Drug Abuse Records. PRIVACY 11.0 DISCLOSURE OF ALCOHOL AND SUBSTANCE/DRUG ABUSE RECORDS Scope: Purpose: All workforce members (employees and non-employees), including employed medical staff, management, and others who have

More information

AVEDA FREDRIC S INSTITUTE DRUG FREE SCHOOL POLICY

AVEDA FREDRIC S INSTITUTE DRUG FREE SCHOOL POLICY AVEDA FREDRIC S INSTITUTE DRUG FREE SCHOOL POLICY The Aveda Fredric s Institute believes that it is very important to provide a safe environment for all of its students and Team Members. Substance abuse,

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Public Health Impacts of 2016 West Virginia Legislation

Public Health Impacts of 2016 West Virginia Legislation Public Health Impacts of 2016 West Virginia Legislation Sherri A. Young, DO, FAAFP WVSOM Summer Seminar North Myrtle Beach, South Carolina June 15, 2016 1 Objectives Passage and implementation of Expedited

More information

Talking with your doctor

Talking with your doctor SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may

More information

Share the important information in this Medication Guide with members of your household.

Share the important information in this Medication Guide with members of your household. Medication Guide BUPRENORPHINE (BUE-pre-NOR-feen) and NALOXONE (nal-ox-one) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine and naloxone sublingual tablets in a secure place away from children.

More information

Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH

Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH Project Title: Genetics of Prostate Cancer Principal Investigator or Faculty Advisor: William J. Catalona, M.D.

More information

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Utah. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view

More information

Acceptable Use Policy - Phone

Acceptable Use Policy - Phone These terms are current as of August 5, 2017 and are subject to change from time to time. Please visit shaw.ca for the most current Terms of Use. Acceptable Use Policy - Phone Introduction Thank you for

More information